4.7 Article

High Rate of Recurrent De Novo Mutations in Developmental and Epileptic Encephalopathies

Journal

AMERICAN JOURNAL OF HUMAN GENETICS
Volume 101, Issue 5, Pages 664-685

Publisher

CELL PRESS
DOI: 10.1016/j.ajhg.2017.09.008

Keywords

-

Funding

  1. Genome Canada
  2. Genome Quebec
  3. Jeanne and Jean-Louis Levesque Foundation
  4. Michael Bahen Chair in Epilepsy Research
  5. Ontario Brain Institute
  6. McLaughlin Foundation
  7. University of Toronto
  8. National Institute of Neurological Disorders and Stroke [RO1 NS069605]
  9. University of Toronto McLaughlin Accelerator Grant in Genomic Medicine [MC-2013-08]
  10. MRC [MC_PC_U127561093] Funding Source: UKRI
  11. Epilepsy Research UK [P1205] Funding Source: researchfish
  12. Medical Research Council [MC_PC_U127561093] Funding Source: researchfish

Ask authors/readers for more resources

Developmental and epileptic encephalopathy (DEE) is a group of conditions characterized by the co-occurrence of epilepsy and intellectual disability (ID), typically with developmental plateauing or regression associated with frequent epileptiform activity. The cause of DEE remains unknown in the majority of cases. We performed whole-genome sequencing (WGS) in 197 individuals with unexplained DEE and pharmaco-resistant seizures and in their unaffected parents. We focused our attention on de novo mutations (DNMs) and identified candidate genes containing such variants. We sought to identify additional subjects with DNMs in these genes by performing targeted sequencing in another series of individuals with DEE and by mining various sequencing datasets. We also performed meta-analyses to document enrichment of DNMs in candidate genes by leveraging our WGS dataset with those of several DEE and ID series. By combining these strategies, we were able to provide a causal link between DEE and the following genes: NTRK2, GABRB2, CLTC, DHDDS, NUS1, RAB11A, GABBR2, and SNAP25. Overall, we established a molecular diagnosis in 63/197 (32%) individuals in our WGS series. The main cause of DEE in these individuals was de novo point mutations (53/63 solved cases), followed by inherited mutations (6/63 solved cases) and de novo CNVs (4/63 solved cases). De novo missense variants explained a larger proportion of individuals in our series than in other series that were primarily ascertained because of ID. Moreover, these DNMs were more frequently recurrent than those identified in ID series. These observations indicate that the genetic landscape of DEE might be different from that of ID without epilepsy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available